This investigation is designed as a prospective, non-randomised, single arm clinical investigation. Data is collected from approximately 120 evaluable subjects, divided into three groups of approximately 40 subjects; infants (0-36 months old), children (3-18 years old) and adults (\>18 years old), with the following indications: eczema, psoriasis and other dry skin conditions. Each subject will be followed during 4 weeks treatment, with a visit at baseline (visit 1), at 2 weeks (visit 2) and at 4 weeks (visit 3) treatment.
Primary Endpoint Skin hydration after treatment with Epaderm Cream up to 4 weeks, evaluated by the subject using a questionnaire. Secondary Endpoints 1. Skin hydration after treatment with Epaderm Cream up to 4 weeks, evaluated by investigator/nurse using a questionnaire. 2. Skin hydration after treatment with Epaderm Cream up to 4 weeks, using a non-invasive device MoistureMeterEpiD. 3. Investigator/nurse evaluation of skin softness after 2 and 4 weeks treatment, using a questionnaire. 4. Subject evaluation of skin softness after 2 and 4 weeks treatment, using a questionnaire. 5. Investigator/nurse evaluation regarding: * Clinical signs/conditions of the affected skin and changes thereof * Did the product prolong the relapse period for flares? 6. Subject evaluation regarding: * Did you use Epaderm Cream according to prescription? * Comfort during treatment * Time of onset of effect * Did the product have the expected effect * Overall impression * Was the investigational device used as a skin cleanser? 7. Concomitant and previous medication and treatment 8. Number of Adverse Device Effects (ADEs) related to the use of Epaderm Cream during the investigation
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
121
The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
Poole Hospital NHS Foundation Trust
Poole, Dorset, United Kingdom
Whiteladies Medical Group
Bristol, United Kingdom
Number of Participants With Improved Skin Moisturization
Participants were considered to have improved moisturization if they responded strongly agree or agree on the questionnaire. Evaluations were carried out in the same affected spot from a scale of Strongly agree, Agree, Neither agree nor disagree, Disagree, Strongly disagree where Strongly agree is the most improved skin moisturization:
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported
Number of Participants With Improved Skin Softness
Participants were considered to have improved softness if they responded strongly agree or agree on the questionnaire. Evaluations were carried out in the same affected spot from a scale of Strongly agree, Agree, Neither agree nor disagree, Disagree, Strongly disagree where Strongly agree is the most improved skin softness.
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported
Number of Participants With Improved Overall Dry Skin/Xerosis
Participants were considered to have improved overall dry skin if they responded 'absent' or 'faint scaling' on the questionnaire. Evaluations were carried out in the same affected spot from a scale of 0= Absent, 1= Faint scaling, faint roughness and dull appearance, 2= Small scales in combination with a few larger scales, slight roughness, whitish appearance, 3= Small and larger scales uniformly distributed, definite roughness, possibly slight redness and possibly a few superficial cracks, 4= Dominated by large scales, advanced roughness, redness present, eczematous changes and cracks where 'absent' or 'fanit scaling' refers to improved overall dry skin.
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported
Number of Participants Who Confirmed Overall Effect and Comfort of Treatment
Participants confirmed the comfort during treatment from a scale of Very Poor, Poor, Average, Good and Excellent where Excellent is considered the most comforting during treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported
Number of Participants With Adverse Device Effects (ADEs)
Number of Adverse Device Effects (ADEs) related to the use of Epaderm Cream during the investigation.
Time frame: Evaluated at every follow-up visit (2 weeks and 4 weeks visit)
Number of Participants Who Reported Applying Epaderm Cream Twice a Day
Frequency of Epaderm Cream application. Participants were asked how often Epaderm Cream was applied either once a day, twice a day, three times a day or four times a day with twice a day application being the most frequent.
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported
Number of Participants With Improvement of Skin Moisturization By Week 4
Participants confirmed the time to visualize improvement of skin moisturization from the range immediately, within 2 weeks or not at all where immediately refers to the most increased improvements seen.
Time frame: Assessed at 2 weeks and 4 weeks visit. Improvement within 4 weeks visit reported.
Number of Participants Who Used Epaderm as a Skin Cleanser
Participants were asked to confirm if the product was used as a skin cleanser by answering yes or no where yes confirmed use of Epaderm cream as a skin cleanser.
Time frame: Assessed at 2 weeks and 4 weeks visit, 4 weeks visit reported where participates answered 'yes'.